Blogs
Welcome to Unibest's Blogs section! Here, you will find valuable insights and in-depth reports covering various topics related to drugs and diseases. Our blogs aim to provide an enhanced understanding of the clinical significance and breakthroughs your clients can make. Stay updated with the latest trends, technological advancements, and industry analyses as we dive deep into the world of pharmaceuticals, giving you the knowledge and resources you need to stay ahead of the competition.

Lurbinectedin

Knowing that you are interested in Lurbinectedin, we have listed articles on similar topics on the website for your convenience. As a professional manufacturer, we hope that this news can help you. If you are interested in learning more about the product, please feel free to contact us.
  • Drug Patent & Exclusivity Expiration Report - Week of June 09 2025

    Drug Patent & Exclusivity Expiration Report - Week of June 09 2025

    2025-06-09

    This week, there are 6 drugs in the patent and exclusivity list. They are: - NOVARTIS PHARMACEUTICALS CORP's TAFINLAR, containing active ingredient DABRAFENIB MESYLATE - NOVARTIS PHARMACEUTICALS CORP's MEKINIST, containing active ingredient TRAMETINIB DIMETHYL SULFOXIDE - COLLEGIUM PHARMACEUTICAL INC's XTAMPZA ER, containing active ingredient OXYCODONE - ELI LILLY AND CO's OLUMIANT, containing active ingredient BARICITINIB - MEDICINES DEVELOPMENT FOR GLOBAL HEALTH's MOXIDECTIN, containing active ingredient MOXIDECTIN - JAZZ PHARMACEUTICALS IRELAND LTD's ZEPZELCA, containing active ingredient LURBINECTEDIN Read More